{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:57:34Z","timestamp":1791849454717,"version":"4.3.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Gastroenterol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12664-024-01643-w","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T04:02:21Z","timestamp":1725336141000},"page":"35-46","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Incidence and risk factors of antituberculosis drug-induced liver injury in India: A systematic review and meta-analysis"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5136-4865","authenticated-orcid":false,"given":"Ramesh","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7061-4433","authenticated-orcid":false,"given":"Rishabh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5117-5443","authenticated-orcid":false,"given":"Sabbu Surya","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7117-1382","authenticated-orcid":false,"given":"Sudhir","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Surya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudheer","family":"Marrapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"1643_CR1","unstructured":"Global tuberculosis report 2023. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2023. Accessed 25 January 2024."},{"key":"1643_CR2","doi-asserted-by":"crossref","unstructured":"Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23:192\u2013202.","DOI":"10.1111\/j.1440-1746.2007.05207.x"},{"key":"1643_CR3","doi-asserted-by":"crossref","unstructured":"Devarbhavi H, Joseph T, Sunil Kumar N, et al. The Indian network of drug-induced liver injury: etiology, clinical features, outcome and prognostic markers in 1288 patients. J Clin Exp Hepatol. 2021;11:288\u201398.","DOI":"10.1016\/j.jceh.2020.11.002"},{"key":"1643_CR4","doi-asserted-by":"crossref","unstructured":"Kumar R, Shalimar, Bhatia V, et al. Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome. Hepatology. 2010;51:1665\u201374.","DOI":"10.1002\/hep.23534"},{"key":"1643_CR5","doi-asserted-by":"crossref","unstructured":"Devarbhavi H, Choudhury AK, Sharma MK, et al. Drug-induce acute-on-chronic liver failure in Asian patients. Am J Gastroenterol. 2019;114:929\u201337.","DOI":"10.14309\/ajg.0000000000000201"},{"key":"1643_CR6","doi-asserted-by":"publisher","first-page":"8266878","DOI":"10.1155\/2022\/8266878","volume":"2022","author":"N Wang","year":"2022","unstructured":"Wang N, Chen X, Hao Z, et al. Incidence and temporal trend of antituberculosis drug-induced liver injury: a systematic review and meta-analysis. J Trop Med. 2022;2022:8266878. https:\/\/doi.org\/10.1155\/2022\/8266878.","journal-title":"J Trop Med"},{"key":"1643_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.18203\/2319-2003.ijbcp20185174","volume":"8","author":"T Nazir","year":"2019","unstructured":"Nazir T, Farhat S, Adil M, Asraf Z, Haque A. Adverse drug reactions associated with first line anti-tubercular drugs, their prevalence and causality assessment in patients on Directly Observed Treatment Short-course (DOTS) in a tertiary care hospital. Int J Basic Clin Pharmacol. 2019;8:147\u201352.","journal-title":"Int J Basic Clin Pharmacol"},{"key":"1643_CR8","doi-asserted-by":"crossref","unstructured":"Kar P, Karna R, Ruttala R, et al. Clinical and molecular risk factors of anti-tubercular therapy induced hepatitis. J Clin Exp Hepatol. 2019;9:200\u20136.","DOI":"10.1016\/j.jceh.2018.06.012"},{"key":"1643_CR9","doi-asserted-by":"crossref","unstructured":"Roy B, Chowdhury A, Kundu S, et al. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 \u2018null\u2019 mutation. J Gastroenterol Hepatol. 2001;16:1033\u20137.","DOI":"10.1046\/j.1440-1746.2001.02585.x"},{"key":"1643_CR10","doi-asserted-by":"crossref","unstructured":"Gupta VH, Amarapurkar DN, Singh M, et al. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India. J Gastroenterol Hepatol. 2013;28:1368\u201374.","DOI":"10.1111\/jgh.12194"},{"key":"1643_CR11","doi-asserted-by":"crossref","unstructured":"Bose PD, Sarma MP, Medhi S, et al. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol. 2011;26:312\u20138.","DOI":"10.1111\/j.1440-1746.2010.06355.x"},{"key":"1643_CR12","doi-asserted-by":"crossref","unstructured":"Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax. 1996;51:132\u20136.","DOI":"10.1136\/thx.51.2.132"},{"key":"1643_CR13","doi-asserted-by":"crossref","unstructured":"Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med. 2002;166:916\u20139.","DOI":"10.1164\/rccm.2108091"},{"key":"1643_CR14","doi-asserted-by":"crossref","unstructured":"Singla N, Gupta D, Birbian N, Singh J. Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity. Tuberculosis (Edinb). 2014;94:293\u20138.","DOI":"10.1016\/j.tube.2014.02.003"},{"key":"1643_CR15","doi-asserted-by":"crossref","unstructured":"Latief M, Dar WR, Sofi N, et al. Novel risk factors and early detection of anti tubercular treatment induced liver injury-looking beyond American Thoracic Society Guidelines. Indian J Tuberc. 2017;64:26\u201332.","DOI":"10.1016\/j.ijtb.2016.11.002"},{"key":"1643_CR16","doi-asserted-by":"crossref","unstructured":"Yadav D, Kumar R, Dixit RK, et al. Association of Nat2 Gene Polymorphism with Antitubercular drug-induced hepatotoxicity in the Eastern Uttar Pradesh Population. Cureus. 2019;11:e4425.","DOI":"10.7759\/cureus.4425"},{"key":"1643_CR17","doi-asserted-by":"crossref","unstructured":"Chatterjee S, Lyle N, Mandal A, Kundu S. GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs. J Clin Pharm Ther. 2010;35:465\u201370.","DOI":"10.1111\/j.1365-2710.2009.01101.x"},{"key":"1643_CR18","doi-asserted-by":"crossref","unstructured":"Kewalramani MS, Vaishnao LS, Jaiswal KM, et al. Evaluation of hepatotoxicity of anti-tuberculosis regimens: a prospective study in tribal population of Central India. J Young Pharm. 2020;12:153\u20137.","DOI":"10.5530\/jyp.2020.12.31"},{"key":"1643_CR19","first-page":"81","volume":"132","author":"R Singla","year":"2010","unstructured":"Singla R, Sharma SK, Mohan A, et al. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res. 2010;132:81\u20136.","journal-title":"Indian J Med Res"},{"key":"1643_CR20","doi-asserted-by":"crossref","unstructured":"Satyaraddi A, Velpandian T, Sharma SK, et al. Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. Int J Tuberc Lung Dis. 2014;18:188\u201395.","DOI":"10.5588\/ijtld.13.0128"},{"key":"1643_CR21","unstructured":"Mandal PK, Mandal A, Bhattacharyya SK. Comparing the daily versus the intermittent regimens of the anti-tubercular chemotherapy in the initial intensive phase in non-HIV, sputum positive, pulmonary tuberculosis patients. J Clin Diagn Res. 2013;7:292\u20135."},{"key":"1643_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4103\/2229-3485.124557","volume":"5","author":"R Sivaraj","year":"2014","unstructured":"Sivaraj R, Umarani S, Parasuraman S, Muralidhar P. Revised national tuberculosis control program regimens with and without directly observed treatment, short-course: a comparative study of therapeutic cure rate and adverse reactions. Perspect Clin Res. 2014;5:16\u20139.","journal-title":"Perspect Clin Res"},{"key":"1643_CR23","doi-asserted-by":"crossref","unstructured":"Gopalan N, Santhanakrishnan RK, Palaniappan AN, et al. Daily vs intermittent antituberculosis therapy for pulmonary tuberculosis in patients with HIV: a randomized clinical trial. JAMA Intern Med. 2018;178:485\u201393.","DOI":"10.1001\/jamainternmed.2018.0141"},{"key":"1643_CR24","doi-asserted-by":"crossref","unstructured":"Raj Mani SS, Iyyadurai R, Mishra AK, et al. Predicting antitubercular drug-induced liver injury and its outcome and introducing a novel scoring system. Int J Mycobacteriol. 2021;10:116\u201321.","DOI":"10.4103\/ijmy.ijmy_15_21"},{"key":"1643_CR25","doi-asserted-by":"crossref","unstructured":"Misra UK, Kumar M, Kalita J. Standard versus sequential anti-tubercular treatment in patients with tuberculous meningitis: a randomized controlled trial. Trans R Soc Trop Med Hyg. 2021;115:94\u2013102.","DOI":"10.1093\/trstmh\/traa144"},{"key":"1643_CR26","doi-asserted-by":"crossref","unstructured":"Juganya TJ, Alagammai P, Karthykayani TJ. Incidence and clinical profile of antituberculosis treatment-induced hepatitis in a tertiary care hospital in southern India. J Clin Diagn Res. 2020;14:OG01\u20135.","DOI":"10.7860\/JCDR\/2020\/46053.14132"},{"key":"1643_CR27","doi-asserted-by":"crossref","unstructured":"Rana SV, Sharma SK, Ola RP, et al. N-acetyltransferase 2, cytochrome P4502E1 and glutathione S-transferase genotypes in antitubercular treatment-induced hepatotoxicity in North Indians. J Clin Pharm Ther. 2014;39:91\u20136.","DOI":"10.1111\/jcpt.12105"},{"key":"1643_CR28","doi-asserted-by":"crossref","unstructured":"Nicoletti P, Devarbhavi H, Goel A, et al. Genetic risk factors in drug-induced liver injury due to isoniazid-containing antituberculosis drug regimens. Clin Pharmacol Ther. 2021;109:1125\u201335.","DOI":"10.1002\/cpt.2100"},{"key":"1643_CR29","doi-asserted-by":"crossref","unstructured":"Akhtar J, Singh S, Verma AK, Pal R, Nath R. A prospective observational study to evaluate Glutathione S-transferase gene polymorphism and its association with Antitubercular drugs induced liver injury in tertiary hospital. Indian J Tuberc. 2022;69341\u20136.","DOI":"10.1016\/j.ijtb.2021.06.006"},{"key":"1643_CR30","doi-asserted-by":"crossref","unstructured":"Sharma SK, Jha BK, Sharma A, et al. Genetic polymorphisms of CYP2E1 and GSTM1 loci and susceptibility to anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis. 2014;18:588\u201393.","DOI":"10.5588\/ijtld.13.0344"},{"key":"1643_CR31","doi-asserted-by":"crossref","unstructured":"Saha A, Shanthi FXM, Winston AB, et al. Prevalence of hepatotoxicity from antituberculosis therapy: a five-year experience from South India. J Prim Care Community Health. 2016;7:171\u20134.","DOI":"10.1177\/2150131916642431"},{"key":"1643_CR32","doi-asserted-by":"crossref","unstructured":"Ali N, Gupta N, Saravu K. Malnutrition as an important risk factor for drug-induced liver injury in patients on anti-tubercular therapy: an experience from a tertiary care center in South India. Drug Discov Ther. 2020;14:135\u20138.","DOI":"10.5582\/ddt.2020.03029"},{"key":"1643_CR33","doi-asserted-by":"crossref","unstructured":"Puri P, Kaur N, Pathania S, et al. Antitubercular therapy induced liver function tests abnormalities in human immunodeficiency virus infected individuals. Med J Armed Forces India. 2017;73:12\u20137.","DOI":"10.1016\/j.mjafi.2016.12.003"},{"key":"1643_CR34","doi-asserted-by":"crossref","unstructured":"Dahale AS, Puri AS, Verma A, et al. Extrapulmonary tuberculosis in cirrhosis: too familiar-too much unknown. J Clin Exp Hepatol. 2022;12:1021\u20132.","DOI":"10.1016\/j.jceh.2021.12.004"},{"key":"1643_CR35","doi-asserted-by":"crossref","unstructured":"Sharma P, Tyagi P, Singla V, et al. Clinical and biochemical profile of tuberculosis in patients with liver cirrhosis. J Clin Exp Hepatol. 2015;5:8\u201313.","DOI":"10.1016\/j.jceh.2015.01.003"},{"key":"1643_CR36","doi-asserted-by":"crossref","unstructured":"Mishra S, Taneja S, De A, Muthu V, et al. Tuberculosis in cirrhosis - a diagnostic and management conundrum. J Clin Exp Hepatol. 2022;12:278\u201386.","DOI":"10.1016\/j.jceh.2021.09.003"},{"key":"1643_CR37","doi-asserted-by":"crossref","unstructured":"Saigal S, Agarwal SR, Nandeesh HP, Sarin SK. Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report. J Gastroenterol Hepatol. 2001;16:1028\u201332.","DOI":"10.1046\/j.1440-1746.2001.02570.x"},{"key":"1643_CR38","doi-asserted-by":"crossref","unstructured":"Anand AC, Seth AK, Paul M, Puri P. Risk factors of hepatotoxicity during anti-tuberculosis treatment. Med J Armed Forces India. 2006;62:45\u20139.","DOI":"10.1016\/S0377-1237(06)80155-3"},{"key":"1643_CR39","doi-asserted-by":"crossref","unstructured":"Agal S, Baijal R, Pramanik S, et al. Monitoring and management of antituberculosis drug induced hepatotoxicity. J Gastroenterol Hepatol. 2005;20:1745\u201352.","DOI":"10.1111\/j.1440-1746.2005.04048.x"},{"key":"1643_CR40","doi-asserted-by":"crossref","unstructured":"Dawra S, Mandavdhare HS, Singh H, et al. Extra-abdominal involvement is associated with antitubercular therapy-related hepatitis in patients treated for abdominal tuberculosis. Clin Exp Hepatol. 2019;5:60\u20134.","DOI":"10.5114\/ceh.2019.83158"},{"key":"1643_CR41","doi-asserted-by":"crossref","unstructured":"Gaude GS, Chaudhury A, Hattiholi J. Drug-induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients. J Family Med Prim Care. 2015;4:238\u201343.","DOI":"10.4103\/2249-4863.154661"},{"key":"1643_CR42","doi-asserted-by":"crossref","unstructured":"Dhali A, Das K, Dhali GK, et al. Abdominal tuberculosis: clinical profile and outcome. Int J Mycobacteriol. 2021;10:414\u201320.","DOI":"10.4103\/ijmy.ijmy_195_21"},{"key":"1643_CR43","doi-asserted-by":"publisher","first-page":"100097","DOI":"10.1016\/j.jctube.2019.100097","volume":"15","author":"A Singh","year":"2019","unstructured":"Singh A, Sahu MK, Panigrahi M, et al. Abdominal tuberculosis in Indians: still very pertinent. J Clin Tuberc Other Mycobact Dis. 2019;15:100097.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"1643_CR44","doi-asserted-by":"crossref","unstructured":"Sharma SK, Jha BK, Sharma A, et al. Genetic polymorphisms of N-acetyltransferase 2 & susceptibility to antituberculosis drug-induced hepatotoxicity. Indian J Med Res. 2016;144:924\u20138.","DOI":"10.4103\/ijmr.IJMR_684_14"},{"key":"1643_CR45","doi-asserted-by":"crossref","unstructured":"Singanayagam A, Sridhar S, Dhariwal J, et al. A comparison between two strategies for monitoring hepatic function during antituberculous therapy. Am J Respir Crit Care Med. 2012;185:653\u20139.","DOI":"10.1164\/rccm.201105-0850OC"},{"key":"1643_CR46","doi-asserted-by":"crossref","unstructured":"Mapamba DA, Sauli E, Mrema L, et al. Impact of N-acetyl cysteine (NAC) on tuberculosis (TB) patients\u2014a systematic review. Antioxidants. 2022;11:2298.","DOI":"10.3390\/antiox11112298"},{"key":"1643_CR47","doi-asserted-by":"crossref","unstructured":"Lang SM, Ortmann J, Rostig S, Schiffl H. Ursodeoxycholic acid attenuates hepatotoxicity of multidrug treatment of mycobacterial infections: a prospective pilot study. Int J Mycobacteriology. 2019;8:89\u201392.","DOI":"10.4103\/ijmy.ijmy_159_18"},{"key":"1643_CR48","doi-asserted-by":"publisher","first-page":"813682","DOI":"10.3389\/fphar.2022.813682","volume":"13","author":"Q Chen","year":"2022","unstructured":"Chen Q, Hu A, Ma A, et al. Effectiveness of prophylactic use of hepatoprotectants for tuberculosis drug-induced liver injury: a population-based cohort analysis involving 6,743 Chinese patients. Front Pharmacol. 2022;13:813682.","journal-title":"Front Pharmacol"},{"key":"1643_CR49","doi-asserted-by":"crossref","unstructured":"Keshavjee S, Gelmanova IY, Shin SS, et al. Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome. Int J Tuberc Lung Dis. 2012;16:596\u2013603.","DOI":"10.5588\/ijtld.11.0591"},{"key":"1643_CR50","doi-asserted-by":"crossref","unstructured":"Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N Engl J Med. 2022;387:810\u201323.","DOI":"10.1056\/NEJMoa2119430"},{"key":"1643_CR51","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4103\/2320-8775.123213","volume":"1","author":"K Sinha","year":"2013","unstructured":"Sinha K, Marak IR, Singh WA. Adverse drug reactions in tuberculosis patients due to directly observed treatment strategy therapy: experience at an outpatient clinic of a teaching hospital in the city of Imphal, Manipur,\u00a0India. J Assoc Chest Physicians. 2013;1:50\u20133.","journal-title":"J Assoc Chest Physicians"},{"key":"1643_CR52","unstructured":"Tak DK, Acharya L, Gowrinath K, Rao Padma GM, Subish P. Safety evaluation of antitubercular therapy under Revised National Tuberculosis Control Programme in India. J Clin Diagn Res. 2009;3:1395\u2013401."},{"key":"1643_CR53","doi-asserted-by":"publisher","first-page":"713","DOI":"10.18203\/2320-6012.ijrms20220524","volume":"10","author":"V Gupta","year":"2022","unstructured":"Gupta V, Guleria TC, Kumar S, et al. Anti-tuberculosis drug induced hepatotoxicity: a study from Himalayan region. Int J Res Med Sci. 2022;10:713\u20136.","journal-title":"Int J Res Med Sci"},{"key":"1643_CR54","doi-asserted-by":"crossref","unstructured":"Vijayalakshmi A, Thanmayi G, Jayakumari S. A prospective study on abnormal LFT patterns in patients receiving antituberculosis therapy. Asian J Pharm Clin Res. 2016;9:136\u20139.","DOI":"10.22159\/ajpcr.2016.v9i5.12756"},{"key":"1643_CR55","doi-asserted-by":"crossref","unstructured":"Subbalaxmi MVS, Soanker R, Lakshmi AV. Evaluation of risk factors for development of anti-tubercular therapy induced hepatotoxicity: a prospective study. Curr Drug Saf. 2020;15:198\u2013204.","DOI":"10.2174\/1574886315666200626164554"}],"container-title":["Indian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-024-01643-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12664-024-01643-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-024-01643-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T03:54:19Z","timestamp":1740196459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12664-024-01643-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1643"],"URL":"https:\/\/doi.org\/10.1007\/s12664-024-01643-w","relation":{},"ISSN":["0254-8860","0975-0711"],"issn-type":[{"value":"0254-8860","type":"print"},{"value":"0975-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"assertion":[{"value":"9 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RK, AK, RP, SSP, SK, HS and SM declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors are solely responsible for the data and the contents of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology\u00a0or the printer\/publishers are responsible for the results\/findings and content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}